Remiges Ventures

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

Founded in 2014, Cyrano Therapeutics develops intranasal therapies for chronic taste and smell disorders. Its lead product, CYR-001, repurposes an approved molecule to restore function with minimal side effects, as demonstrated in a pilot study. The company aims to improve patients' quality of life by addressing these often overlooked conditions.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Kupando is a biopharmaceutical company focused on developing immunostimulatory agents targeting toll-like receptors. Its mission is to create affordable immunotherapy options for cancer patients and prevent infectious diseases.

Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Viage Therapeutics is a neuroscience company established in 2018, focusing on the development of innovative neurotherapeutics. The company is dedicated to discovering and creating a new class of drugs aimed at treating psychiatric and inflammatory diseases, including conditions such as depression, anxiety, and gastrointestinal disorders. Through its groundbreaking research, Viage Therapeutics seeks to address significant unmet medical needs, providing healthcare professionals with access to novel therapeutic options that could improve patient outcomes.

Capacity Bio is a therapeutics company dedicated to the field of mitophagy, which involves the process of removing damaged mitochondria to maintain cellular health. The company is focused on developing a comprehensive and advanced platform for mitophagy therapeutics aimed at restoring mitochondrial quality control in various diseases. By targeting fundamental biological processes, Capacity Bio seeks to deliver radical therapeutic benefits that can enhance healthcare outcomes. The company's innovative approach positions it at the forefront of mitochondrial research and therapeutic development.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Founded in 2014, Cyrano Therapeutics develops intranasal therapies for chronic taste and smell disorders. Its lead product, CYR-001, repurposes an approved molecule to restore function with minimal side effects, as demonstrated in a pilot study. The company aims to improve patients' quality of life by addressing these often overlooked conditions.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Tranquis Therapeutics is a biotechnology company developing innovative immuno-therapeutics targeting myeloid immune cell dysfunction linked to various neurodegenerative and aging-related disorders. Its lead candidate, TQS-168, has shown promising results in preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

ENB Therapeutics develops small molecule inhibitors targeting the endothelin B receptor to enhance cancer immunotherapy. Founded in 2015, it aims to overcome drug resistance and reduce tumor growth, with its lead product ENB-001 granted Orphan Drug Designation by the FDA.

KisoJi Biotechnology is an early-stage biotech company specializing in antibody development for cancer treatment. Its innovative platform combines multi-species transgenic mice with AI-driven antibody fingerprinting, enabling the identification of optimal lead candidates and the creation of robust, manufacturable multi-specific antibodies.

OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.

Mitoconix Bio Ltd is a biotechnology company established in 2016 and headquartered in Jerusalem, Israel, focused on developing innovative therapies aimed at enhancing mitochondrial health to treat neurodegenerative diseases. The company employs a disease-modifying approach that targets the functions of mitochondria, which are essential for generating ATP, regulating calcium, and maintaining cellular balance. Mitochondria play a crucial role in neuron function, undergoing constant changes in structure through processes known as fission and fusion. Disruptions in these processes can lead to reduced energy production and increased oxidative stress, contributing to cellular dysfunction and death. Mitoconix's lead drug is a first-in-class inhibitor designed to counteract pathological mitochondrial fragmentation and has shown promising efficacy in preclinical models of Huntington's disease and Parkinson's disease, as well as beneficial effects in patient-derived cells associated with these conditions and Alzheimer's disease.